Atopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business Update
May 07 2024 - 4:09AM
Geneva (Switzerland), May 7, 2024 – Atopia
Therapeutics, a leader in the development of breakthrough asthma
and allergy therapies, today announced the appointment of Dr.
Grégoire Chevalier as Chief Executive Officer (CEO). Formerly known
as HpVac, the Company has repositioned itself under the new name
Atopia Therapeutics to better reflect its commitment to addressing
the growing global burden of atopic diseases.
Grégoire Chevalier brings over 10 years of
research and drug development experience to Atopia Therapeutics. He
joins the Company from Enterome, a leading French biotechnology
company focused on innovative immunotherapy for cancer, where he
spent the last 5 years directing several R&D programs.
Throughout his career, he has demonstrated a strong ability to
drive strategic initiatives and foster a culture of innovation and
excellence. Grégoire will now lead Atopia’s strategy and
development and strengthen the overall organization.
Under Grégoire Chevalier’s leadership, Atopia
Therapeutics will continue the development of novel treatments that
address the underlying mechanisms of atopic diseases. Its lead
compound ATP-R13 (formerly: HpVac-R13) is designed as a first-line
preventive and therapeutic treatment for a number of type-2 atopic
diseases, including asthma, allergic rhinitis, food allergies and
atopic dermatitis. The compound has already generated promising
data in preclinical studies, including beneficial effects on airway
hyperresponsiveness, airway remodeling, and inflammation in mouse
models of allergic asthma.
“As we embark on our next phase of growth and
expansion, we are thrilled to welcome Grégoire Chevalier as the new
CEO of Atopia Therapeutics,” said Board Member Jacques Billy, CFO
of Atopia Therapeutics. “Grégoire’s deep industry expertise,
coupled with his passion for scientific innovation and
patient-centric approach, make him the ideal leader to steer our
company towards continued success.”
“I am delighted and grateful to have the
opportunity to lead Atopia Therapeutics during this exciting period
of growth and transformation,” said Grégoire Chevalier, CEO of
Atopia Therapeutics. “I am inspired by the Company’s commitment to
advancing cutting-edge therapies for allergic diseases, and I look
forward to working with the talented team to deliver impactful
solutions for patients in need.”
As part of the rebranding initiative, Atopia
Therapeutics has unveiled a refreshed corporate identity, including
a new logo and website (www.atopiatx.com), designed to reflect the
Company’s innovative spirit and forward-thinking approach.
###
About Atopia Therapeutics:Atopia
Therapeutics is a leading biotech company dedicated to
revolutionizing the treatment of allergic diseases via novel
microbiome-based therapeutics. Formerly known as HpVac, Atopia
Therapeutics is committed to developing innovative therapies that
target the underlying causes of allergies, offering hope and relief
to patients worldwide. Its lead compound ATP-R13 (formerly:
HpVac-R13) is designed as an oral first-line preventive and
therapeutic treatment against asthma, eczema, food allergies, and
related type-2 atopic diseases. ATP-R13 remains in the stomach,
interacts with dendritic cells and macrophages in the host’s lamina
propria, and induces the production of tolerizing dendritic cells
and regulatory T cells (Tregs), which then migrate to draining
lymph nodes, before dispersing to other target organs (lungs, skin,
etc.). ATP-R13 has been shown to induce a state of tolerance and
reduce inflammation in preclinical studies. Atopia Therapeutics is
based in Geneva, Switzerland. For more information, please visit
www.atopiatx.com.
For media inquiries or further information,
please contact:
Atopia Therapeutics, SADr. Jeffrey Shaw, COOCampus
Biotech – Innovation Center15, Avenue de SécheronCH-1202 Geneva,
Switzerlandinfo@atopiatx.comTel. +41 22 794 40 20Tel. +41 78 664 55
83
Media InquiriesakampionDr. Ludger Wess / Ines-Regina Buth
Managing Partners info@akampion.comTel. +49 40 88 16 59 64
/Tel. +49 30 23 63 27 68